What is more for cancer patients: increased screening or treatment innovation?

Let’s get this out of the way: both are clearly important.  Within appropriate screening, patients don’t get the treatment they need.  Further, delayed screening can make treatments less effective if the cancer has progressed or metastasized.  On the other hand, without effective treatment, screening won’t have a major impact on patient outcomes. The question is,…

What does “value” really mean?

An interesting article in Stat makes the important point that although there is much talk about “value” in the media and health policy world, the exact definition of “value” depends on your presepective. But a survey released Wednesday by the University of Utah shows that, in health care, value has no universal meaning — 88 percent of doctors…

Off-label prescribing

How frequently are pharmaceuticals used off label?  Perhaps more than you think.  Although these figures are a bit dated, Tabarrok (2000) details the extent of off-label prescribing in the U.S. as follows: According to a study by the U.S. General Accounting Office, 56 percent of cancer patients have been given non-FDA-approved prescriptions, and 33 percent…

IVI Model highlights ACR Conference

As reported in a Academy of Managed Care & Specialty Pharmacy newsletter, titled “Mathematical Model Aims to Improve Cost-Effectiveness of Rheumatology Treatment“, the Innovation and Value Initiative’s is highlighted from the American College of Rheumatology conference.  Here is an excerpt: Biological therapies for moderate to severe rheumatoid arthritis have significantly improved treatment and prognosis. However,…